Onyx Pharmaceuticals and Bayer HealthCare have restructured their partnership for the global development and marketing of Nexavar (sorafenib) tablets, and entered into a new agreement for Bayer’s regorafenib, a late-stage oncology compound.
 
Bayer will have the final say for global development and commercialization of regorafenib and Onyx will receive a royalty on any future global sales in oncology. Both companies will promote regorafenib in the U.S.  

Under the revised Nexavar collaboration, Onyx and Bayer are free to use their respective Nexavar sales forces to promote regorafenib and additional products outside of the collaboration in the future. Bayer will purchase Onyx’s royalty rights for sales of the product in Japan in exchange for a one-time payment to Onyx.

“These new agreements strengthen the collaboration and provide Onyx the opportunity to participate significantly in the market potential of regorafenib,” said N. Anthony Coles, M.D., president and chief executive officer of Onyx Pharmaceuticals. “Onyx and Bayer are committed to benefitting patients worldwide and ensuring that the potential of both Nexavar and regorafenib is fully realized.”

“These agreements set the stage for the next chapter in our successful partnership,” said Dr. Joerg Reinhardt, chairman of the Bayer HealthCare Executive Committee. “Innovation is central to Bayer’s mission ‘Science for a Better Life,’ and our ongoing collaboration with Onyx demonstrates the priority we place on working with partners to identify, develop and commercialize new medicines to meet unmet or under-served medical needs.”